The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors

被引:58
作者
Yang, JC [1 ]
Perry-Lalley, D [1 ]
机构
[1] NCI, Surg Branch, Bethesda, MD 20892 USA
来源
JOURNAL OF IMMUNOTHERAPY | 2000年 / 23卷 / 02期
关键词
cytotoxic T lymphocyte; endogenous retrovirus; murine tumor; tumor antigen;
D O I
10.1097/00002371-200003000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, significant progress has been made in identifying specific tumor-associated antigens recognized by T cells and defining the specific peptide epitopes within these proteins that are processed and presented on class 1 major histocompatibility antigens. Most of these antigens have been identified in human melanoma, where many of them appear to be tissue-specific, nonmutated proteins expressed by melanoma and normal melanocytes but not by other tissues. There has been much less progress in identifying the tumor antigens on murine tumors that are recognized by T cells, and this has restricted the development of preclinical animal models for immunotherapy. The authors previously described a method for generating tumor-reactive T cells from murine tumors (tumor infiltrating lymphocytes) that are CD8(+) T cells recognizing autologous tumor and that can inhibit established tumor on adoptive transfer. Here the authors show that the envelope protein of an endogenous murine retrovirus of the AKV family, found in the germline of the C57BL/6 mouse, is recognized by tumor-infiltrating lymphocytes from two histologically different tumors syngeneic to that mouse strain. Furthermore, the authors identify the specific 9-amino acid peptide from the p15E transmembrane component of this envelope protein that is recognized in the context of major histocompatibility complex Kb, show that it is naturally presented and recognized on several other H-2(b) tumors, and that cytotoxic T lymphocytes specific for this epitope are therapeutic for these antigen-expressing tumors on adoptive transfer.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 16 条
  • [1] Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
    Bloom, MB
    PerryLalley, D
    Robbins, PF
    Li, Y
    ElGamil, M
    Rosenberg, SA
    Yang, JC
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) : 453 - 459
  • [2] Cormier JN, 1997, CANCER J, V3, P37
  • [3] HAYASHI H, 1992, J IMMUNOL, V149, P1223
  • [4] The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
    Huang, AYC
    Gulden, PH
    Woods, AS
    Thomas, MC
    Tong, CD
    Wang, W
    Engelhard, VH
    Pasternack, G
    Cotter, R
    Hunt, D
    Pardoll, DM
    Jaffee, EM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) : 9730 - 9735
  • [5] CLONING OF THE GENE CODING FOR A SHARED HUMAN-MELANOMA ANTIGEN RECOGNIZED BY AUTOLOGOUS T-CELLS INFILTRATING INTO TUMOR
    KAWAKAMI, Y
    ELIYAHU, S
    DELGADO, CH
    ROBBINS, PF
    RIVOLTINI, L
    TOPALIAN, SL
    MIKI, T
    ROSENBERG, SA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 3515 - 3519
  • [6] CTL INDUCTION BY A TUMOR-ASSOCIATED ANTIGEN OCTAPEPTIDE DERIVED FROM A MURINE LUNG-CARCINOMA
    MANDELBOIM, O
    BERKE, G
    FRIDKIN, M
    FELDMAN, M
    EISENSTEIN, M
    EISENBACH, L
    [J]. NATURE, 1994, 369 (6475) : 67 - 71
  • [7] Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells
    Marincola, FM
    Rivoltini, L
    Salgaller, ML
    Player, T
    Rosenberg, SA
    [J]. JOURNAL OF IMMUNOTHERAPY, 1996, 19 (04) : 266 - 277
  • [8] PREHN RT, 1965, FED PROC, V24, P1019
  • [9] MCH LIGANDS AND PEPTIDE MOTIFS - FIRST LISTING
    RAMMENSEE, HG
    FRIEDE, T
    STEVANOVIC, S
    [J]. IMMUNOGENETICS, 1995, 41 (04) : 178 - 228
  • [10] Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
    Rosenberg, SA
    Yang, JC
    Schwartzentruber, DJ
    Hwu, P
    Marincola, FM
    Topalian, SL
    Restifo, NP
    Dudley, ME
    Schwarz, SL
    Spiess, PJ
    Wunderlich, JR
    Parkhurst, MR
    Kawakami, Y
    Seipp, CA
    Einhorn, JH
    White, DE
    [J]. NATURE MEDICINE, 1998, 4 (03) : 321 - 327